GLP-1 Drugs Linked to Better Outcomes After Spinal Deformity Surgery | Research

The takeaway

Patients on GLP-1 receptor agonists had significantly lower rates of pseudoarthrosis, hardware failure, infections, blood clots, readmissions, and mortality after adult spinal deformity surgery.

7 outcomes improved
GLP-1 users had significantly better results across pseudoarthrosis, hardware failure, wound, infection, clots, readmission, and mortality

What the researchers found

At 1 and 2 years post-surgery, GLP-1 agonist users had significantly lower odds of pseudoarthrosis, hardware failures, wound dehiscence, infections, thromboembolic events, readmissions, and mortality after spinal deformity correction.

Why it matters

Spinal deformity surgery has high complication rates. If GLP-1 drugs truly reduce these complications, they could become an important part of surgical preparation and recovery protocols for spine patients.

How the study worked

Multicenter retrospective cohort study using the TriNetX Global Collaborative Database (2005-2025) with 1:1 propensity-score matching by demographics and comorbidities.

What this study cannot tell us

Retrospective observational design. Patients on GLP-1 drugs may differ systematically from non-users in ways not captured by propensity matching. The mechanism by which GLP-1 drugs improve surgical outcomes is not established.

How to read the evidence

Large multicenter retrospective study with propensity-score matching. Consistent benefits across multiple outcomes, but observational design limits causal conclusions.

When this study was published

Published in 2025 using data through 2025, reflecting the most current evidence on GLP-1 drugs and surgical outcomes.

The bigger picture

This adds to growing evidence that GLP-1 peptide drugs have anti-inflammatory and tissue-healing properties that extend far beyond blood sugar control, potentially benefiting surgical patients across specialties.

Questions still open

What biological mechanisms explain GLP-1 drugs' apparent benefits for bone healing and surgical recovery?
Should GLP-1 therapy be considered preoperatively for spine surgery patients, even without diabetes?
Do these benefits extend to other types of orthopedic or major surgeries?

Common questions

How could diabetes drugs help with spine surgery recovery?

GLP-1 receptor agonists appear to have anti-inflammatory and tissue-healing properties beyond blood sugar control. These effects may promote bone healing, reduce infection risk, and improve overall surgical recovery.

Should I start a GLP-1 drug before spine surgery?

This observational study shows promising associations, but it's too early for formal recommendations. Discuss with your surgeon and endocrinologist whether GLP-1 therapy might be appropriate in your specific situation.

Read the original research

Association of glucagon-like peptide-1 agonist therapy with postsurgical outcomes following multilevel correction for adult spinal deformity: a propensity score-matched analysis.

Asian spine journal

View on PubMed ↗Publisher’s paper ↗

Citation

D'Amico, Cassandra; Jacques, Benjamin; Ferdon, Robert; Silvestre, Jason; Lewis, Stephen; Nielsen, Christopher; Glaser, John; Reitman, Charles; Lawrence, James; Ravinsky, Robert. (2026). Association of glucagon-like peptide-1 agonist therapy with postsurgical outcomes following multilevel correction for adult spinal deformity: a propensity score-matched analysis.. Asian spine journal. https://doi.org/10.31616/asj.2025.0407